Rajasthan Antibiotics to raise Rs 50 crore VC funding

The company plans to generate a revenue of INR 500 crores by 2020 and strengthening its position in the ever-growing niche segment of Steriles

New Delhi: Rajasthan Antibiotics Limited (RAL), a leading pharmaceutical company, is planning to raise an amount of Rs 50 crores through venture capital (VC) funding by August-September 2017. BIORx Venture Advisors (BIORx) has been mandated to syndicate funds. The funding would be pumped into company expansion through Greenfield and Brownfield. BIORx works as a financial and strategic partner for the life-sciences industry.
RAL was incorporated on March 17, 1986, and commenced commercial production in the year 1991. RAL is engaged in the manufacturing of bulk drugs, also known as active pharmaceutical ingredients (API’s). The company has a diversified product mix that largely caters to two therapeutic segments, namely, Anti-Infective and gastroenterology.
In the past 25 years, RAL has grown both in size and reputation to become the nation’s largest producer of injectable antibiotics. Mr Ashish Pruthi, MD, RAL, said, “Our next target is to generate a revenue of INR 500 crores by 2020 and strengthening our position in the ever-growing niche segment of Steriles.”
RAL, one of the fastest growing pharmaceutical companies in North India and having its corporate office based out of Delhi are always on the move to develop innovative products at very competitive prices. It is also very efficiently harnessing its funds for improving manufacturing facilities and upgrading the existing R&D department. The company has got a great clientele base not only in India but also in Europe and countries like China, Brazil, Indonesia, Bangladesh and UAE where it has already made its presence felt.